Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTXNASDAQ:HRTXNASDAQ:RAPPNASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.61-3.6%$2.10$1.55▼$7.66$91.23M2.521.43 million shs1.26 million shsHRTXHeron Therapeutics$2.26-2.2%$2.00$1.04▼$3.93$344.27M1.552.37 million shs632,303 shsRAPPRapport Therapeutics$10.05+3.6%$12.54$6.43▼$29.74$366.79MN/A177,365 shs108,870 shsSLDBSolid Biosciences$4.32-1.1%$4.41$2.88▼$13.47$334.77M1.98837,848 shs496,644 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics-3.59%-9.55%-21.46%-26.48%-67.14%HRTXHeron Therapeutics-2.16%-5.04%+32.16%+45.81%-17.52%RAPPRapport Therapeutics+3.61%+3.40%-8.97%-47.19%+1,004,999,900.00%SLDBSolid Biosciences-1.14%-6.09%-18.34%+1.89%-69.68%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDTXBlack Diamond Therapeutics3.3415 of 5 stars3.53.00.00.03.32.51.3HRTXHeron Therapeutics3.8407 of 5 stars3.50.00.04.23.71.70.6RAPPRapport Therapeutics1.7103 of 5 stars3.50.00.00.02.31.70.6SLDBSolid Biosciences3.3781 of 5 stars3.72.00.00.02.34.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 3.00Buy$14.60806.83% UpsideHRTXHeron Therapeutics 3.00Buy$5.67150.74% UpsideRAPPRapport Therapeutics 3.00Buy$35.00248.26% UpsideSLDBSolid Biosciences 3.33Buy$15.67262.65% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, RAPP, SLDB, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/19/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.003/18/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $12.003/13/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $11.003/10/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $20.003/7/2025BDTXBlack Diamond TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/7/2025BDTXBlack Diamond TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00 ➝ $11.003/7/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/28/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.002/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.001/10/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.001/8/2025SLDBSolid BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.00(Data available from 3/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond TherapeuticsN/AN/AN/AN/A$2.26 per shareN/AHRTXHeron Therapeutics$144.29M2.39N/AN/A($0.23) per share-9.83RAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ASLDBSolid Biosciences$8.09M41.38N/AN/A$6.27 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics-$82.44M-$1.27N/AN/AN/AN/A-68.08%-49.65%5/8/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.09N/AN/AN/A-20.31%N/A-12.72%5/6/2025 (Estimated)RAPPRapport Therapeutics-$34.79M-$13.84N/AN/AN/AN/AN/AN/A6/2/2025 (Estimated)SLDBSolid Biosciences-$96.01M-$3.04N/AN/AN/AN/A-58.75%-47.84%5/13/2025 (Estimated)Latest BDTX, RAPP, SLDB, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/6/2025Q4 2024BDTXBlack Diamond Therapeutics-$0.31-$0.28+$0.03-$0.28N/AN/A2/27/2025Q4 2024HRTXHeron Therapeutics-$0.03$0.02+$0.05$0.02$37.37 million$40.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A5.555.55HRTXHeron TherapeuticsN/A2.281.74RAPPRapport TherapeuticsN/A45.9145.91SLDBSolid BiosciencesN/A7.857.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%HRTXHeron Therapeutics80.01%RAPPRapport TherapeuticsN/ASLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics8.87%HRTXHeron Therapeutics5.76%RAPPRapport TherapeuticsN/ASLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9056.66 million51.57 millionOptionableHRTXHeron Therapeutics300152.33 million143.33 millionOptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ASLDBSolid Biosciences10077.49 million35.05 millionOptionableBDTX, RAPP, SLDB, and HRTX HeadlinesRecent News About These CompaniesTruist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB)March 21, 2025 | markets.businessinsider.comSolid Biosciences Inc. (SLDB): Among Top Insider Purchases Last MonthMarch 14, 2025 | insidermonkey.comJPMorgan Chase & Co. Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock PriceMarch 14, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Stock Price Up 0.5% - Still a Buy?March 13, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of "Buy" from BrokeragesMarch 13, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Short Interest UpdateMarch 13, 2025 | marketbeat.comSolid Biosciences (SLDB) Receives a Buy from J.P. MorganMarch 12, 2025 | markets.businessinsider.comSolid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 12, 2025 | globenewswire.comEquities Analysts Offer Predictions for SLDB Q1 EarningsMarch 12, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading Down 4.9% - What's Next?March 11, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Shares Down 3.1% - Here's What HappenedMarch 11, 2025 | marketbeat.comSolid Biosciences price target raised to $20 from $16 at H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comSolid Biosciences (SLDB) Gets a Buy from Truist FinancialMarch 10, 2025 | markets.businessinsider.comHC Wainwright Increases Solid Biosciences (NASDAQ:SLDB) Price Target to $20.00March 10, 2025 | marketbeat.comFY2026 Earnings Forecast for SLDB Issued By William BlairMarch 10, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives "Buy" Rating from Chardan CapitalMarch 8, 2025 | marketbeat.comSolid Biosciences Reports Positive Data from Duchenne Gene Therapy Trial and Provides Business UpdateMarch 8, 2025 | nasdaq.comSolid Biosciences (SLDB) Gets a Buy from Chardan CapitalMarch 7, 2025 | markets.businessinsider.comSolid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Misses Expectations By $0.12 EPSMarch 7, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Releases Earnings Results, Misses Expectations By $0.12 EPSMarch 7, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Stock Price Down 1.1% - What's Next?March 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Broaden Your ETF Exposure With These 3 Overlooked FundsBy Nathan Reiff | March 6, 2025View Broaden Your ETF Exposure With These 3 Overlooked FundsBDTX, RAPP, SLDB, and HRTX Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.61 -0.06 (-3.59%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.60 -0.01 (-0.62%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Heron Therapeutics NASDAQ:HRTX$2.26 -0.05 (-2.16%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.26 0.00 (-0.22%) As of 03/28/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Rapport Therapeutics NASDAQ:RAPP$10.05 +0.35 (+3.61%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$10.05 0.00 (0.00%) As of 03/28/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Solid Biosciences NASDAQ:SLDB$4.32 -0.05 (-1.14%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$4.32 +0.00 (+0.12%) As of 03/28/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan: The 'NVIDIA of Banking' Poised for More Gains? Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback Joby Aviation Stock: Analyst Confidence and Smart Money Align Ibotta Stock: Why the Buyback Looks Like a Bullish Bet Archer Aviation Stock Sees Surge in Institutional Buys How Can Tomahawk 6 Contribute to Broadcom's AI Growth Story? Microsoft’s Big Malaysia Bet Could Pay Off for Investors Intuitive Machines Gains After Earnings Beat, NASA Missions Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
